IRWD241220C22500
- 0.05
- 0.000.00%
Ironwood Pharmaceuticals Newsroom
Ironwood Pharmaceuticals Shares Surge on Competitor's Woes
Wells Fargo Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $12
Here's Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD)
Jefferies Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Cuts Target Price to $12
Ironwood Pharmaceuticals On Pace for Largest Percent Increase Since January 2014 -- Data Talk
Beam Therapeutics Picks Ironwood Pharmaceuticals Finance and Operations Chief as CFO
Why Investors Shouldn't Be Surprised By Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) 26% Share Price Plunge
Ironwood Pharmaceuticals, Inc.: Effective Dec. 18, CEO Thomas McCourt Will Serve as Principal Financial Officer on Interim Basis >IRWD
Express News | Ironwood Pharmaceuticals Inc - Sravan K. Emany to Resign as Svp, COO, and CFO
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
US Manufacturing Index Rises To 43, Highest Since 2020
Shareholders Can't Ignore US$5.7m Of Sales By Ironwood Pharmaceuticals Insiders
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call Transcript
Ironwood Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
JMP Securities Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $23
Positive Outlook for Ironwood Pharmaceuticals: LINZESS Growth and Apraglutide Potential Drive Buy Rating
Ironwood Pharmaceuticals Non-GAAP EPS of $0.02 Misses by $0.08, Revenue of $91.6M Beats by $0.3M
Express News | Ironwood Pharmaceuticals Inc: Maintains Full Year 2024 Financial Guidance
Ironwood Pharmaceuticals | 8-K: Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
GUIDANCE: (IRWD) IRONWOOD PHARMACEUTICALS Sees Fiscal Year 2024 Revenue Range $350M - $375M